Screening for Albuminuria in High-Risk Populations

Initial Screening Recommendations

The American Diabetes Association and the National Kidney Foundation recommend that all patients with diabetes, hypertension, or cardiovascular disease should be screened for albuminuria using spot urine ACR at least annually, with testing initiated 5 years after diagnosis for type 1 diabetes and immediately at diagnosis for type 2 diabetes 1, 2, 3
The American Journal of Kidney Diseases suggests that diabetes mellitus patients should begin ACR screening 5 years after diagnosis for type 1 diabetes, but start immediately at diagnosis for type 2 diabetes due to uncertain disease onset 4, 2, 3
The Kidney International journal recommends that hypertension patients should be screened annually, as over 20% have undiagnosed albuminuria (ACR ≥30 mg/g), yet only 7% are currently tested 1
The Kidney International journal also recommends that cardiovascular disease patients should be screened annually, as this population has CKD prevalence exceeding 40% 1
The American Journal of Kidney Diseases suggests that individuals with a family history of CKD or ESRD should undergo annual screening as part of regular health examination 4

The Diabetes Care journal recommends that patients with normal or mildly increased albuminuria (ACR <30 mg/g) should continue annual screening in all high-risk populations 3
The Annals of Internal Medicine journal suggests that patients with moderately increased albuminuria (ACR 30-299 mg/g) and eGFR ≥60 mL/min/1.73 m² should monitor ACR and eGFR annually 5, 3
The Annals of Internal Medicine journal also recommends that patients with moderately increased albuminuria (ACR 30-299 mg/g) and eGFR 45-59 mL/min/1.73 m² should monitor every 6 months 5
The Annals of Internal Medicine journal suggests that patients with moderately increased albuminuria (ACR 30-299 mg/g) and eGFR 30-44 mL/min/1.73 m² should monitor every 3-4 months 5

The American Journal of Kidney Diseases recommends that patients should be retested within 6 months after initiating antihypertensive therapy or lipid-lowering treatment to assess treatment response 4
The American Journal of Kidney Diseases suggests that if treatment achieves significant reduction in albuminuria, patients should return to annual monitoring 4

The American Journal of Kidney Diseases and the Diabetes Care journal recommend that any ACR >30 mg/g should be confirmed with 2 out of 3 positive tests collected over 3-6 months before diagnosing persistent albuminuria 4, 2

The American Journal of Kidney Diseases and the Diabetes Care journal recommend that first morning void specimen is preferred for children, adolescents, and adults to minimize variability and avoid orthostatic proteinuria 4, 2
The Diabetes Care journal and the Annals of Internal Medicine journal suggest that spot untimed urine samples are acceptable and preferred over 24-hour collections, which are burdensome and add little accuracy 2, 5